AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03402516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 26Fr resector
Description: hysteroscopic myomectomy with a 26Fr resector after cervical dilatation until Hegar bougie number 10
Study NCT01017276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral
Study NCT04066205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLEEPSAMRT
Description: SLEEPSMART is a web-based intervention that adapted and modified components from the Transdiagnostic Sleep and Circadian intervention for youth and included four cross-cutting components (sleep complaint, education, behavior change and motivation, and goal-setting) that were integrated into each module. To begin the intervention, participants were provided a link to the SLEEPSMART intervention website for one of the above modules and an online sleep coach each week. At the end of each week, children and parents uploaded the weekly activities and goals via the REDCap link and set up a meeting with the sleep coach to review. The modules took 20 to 30 minutes to complete.
Study NCT00682643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone furoate nasal spray
Description: fluticasone furoate nasal spray
Study NCT00682643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle placebo nasal spray
Description: placebo
Study NCT01875185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Aspirin 81 mg orally daily for 7 days
Study NCT04166526 — intervention group
Intervention type: DEVICE
Intervention: FDNIRS-DCS
Description: FDNIRS-DCS measurements will be performed at the same time as all MRI scans. Participants in Group 4 will have additional measurements before, during, and after the their scheduled transfusion.
Study NCT03208426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracycline (BQ10)
Description: Tetracycline (Brand name: Tetracycline Capsule ) 500mg qid for 10 days
Study NCT00743197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81 mg daily
Study NCT00743197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Lisinopril 10 mg every night
Study NCT00743197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 20 mg every night
Study NCT00743197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza
Description: Lovaza 1 gram daily
Study NCT00743197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Lifestyle Changes
Description: Therapeutic lifestyle changes will be initiated with the assistance of a dietician, including diet counseling, exercise recommendation, and weight maintenance/weight loss.
Study NCT04954014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive best available treatment (BAT) for COVID-19 plus a single dose of bevacizumab calculated as 7,5 mg/kg diluted in 250cc of saline solution during 90 minutes.
Study NCT04954014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: Patients will receive best available treatment for COVID-19.
Study NCT02277457 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-Adaptive RT
Description: All patients will be treated with response-driven PET-adaptive RT. The radiation dose will be delivered in greater than or equal to 2.2 Gy per daily fraction to FDG-PET/CT-guided target volumes with the treatment duration limited to 30 fractions and total radiation dose limited to 66-80.4 Gy.
Study NCT02277457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg once daily
Study NCT02277457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: 250 mg twice daily
Study NCT02304120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive postural training
Study NCT02304120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Study NCT02304120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: All participating patients will attend usual care according to their treatment plan (taking part in the study does not affect the treatment plan). A physiotherapy referral requests 9 treatments, each of which takes 30 minutes. These will take place twice a week for 4.5 weeks. The study protocol does not dictate the content of the physiotherapy sessions themselves, but detailed documentation of provided treatments is required (therapy documentation sheet). Additionally, the aim of the physiotherapy sessions should always include reduction of muscular imbalances and optimisation of posture.
Study NCT02304120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: All participating patients will attend usual care according to their treatment plan (taking part in the study does not affect the treatment plan). A physiotherapy referral requests 9 treatments, each of which takes 30 minutes. These will take place twice a week for 4.5 weeks. The study protocol does not dictate the content of the physiotherapy sessions themselves, but detailed documentation of provided treatments is required (therapy documentation sheet). Additionally, the aim of the physiotherapy sessions should always include reduction of muscular imbalances and optimisation of posture.
Study NCT03249181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Patients randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs
Study NCT03249181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (EFV + 2 NRTI backbone)
Description: Patients randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy.
Study NCT00720486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Juvenile Justice Anger Management (JJAM) for Girls
Description: JJAM will include two 1.5-hour group treatment sessions per week for 8 weeks. JJAM sessions will be manual based and will be designed to help youth develop skills in the following areas: identifying different types of physical and relational aggression, recognizing early warning signs of anger, avoiding anger-provoking situations, managing anger to prevent aggression, solving problems, communicating about anger-related events, and repairing relationships damaged by anger-related behaviors.
Study NCT00720486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual will include standard activities in the female juvenile justice program.
Study NCT00720486 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual will include standard activities in the female juvenile justice program.
Study NCT03259581 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization
Description: Delivery of lipiodol, chemotherapy (Deoxyrubicin), and particles (embosphere particles) to the arteries feeding hepatocellular carcinoma. While both chemotherapy and particles are delivered this is a single procedure in which the chemotherapy is delivered followed immediately by particles.
Study NCT03467477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: 370 megabecquerel (MBq) IV single-dose
Study NCT03467477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET Scan
Description: positron emission tomography (PET) scan of the brain
Study NCT03632174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Ointment with L. reuteri
Description: Topical Ointment containing live Lactobacillus reuteri DSM17938 applied twice daily in dry areas of the entire body
Study NCT03632174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Ointment without L. reuteri
Description: Topical Ointment that does not contain Lactobacillus reuteri DSM17938 applied twice daily in dry areas of the entire body
Study NCT03317197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only
Study NCT03317197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Group 1
Description: Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle)
Study NCT03317197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Group 2
Description: Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
Study NCT03317197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Group 3
Description: Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
Study NCT04209920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD-CAM milled PMMA crown
Description: the patient will receive a full coverage restoration for hypomineralized first permanent molar in patient suffering from molar incisor hypomineralization using PMMA disks using a CAD-CAM technology.
Study NCT04209920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cast metal coping using nickel chromium alloy
Description: the patient will receive a full coverage restoration for hypomineralized first permanent molar in patient suffering from molar incisor hypomineralization using Nickel Chromium alloy to make a Cast Coping.
Study NCT01932034 — intervention group
Intervention type: DEVICE
Intervention: BestDose Computer Software
Description: BestDose is made by the USC Laboratory of Applied Pharmacokinetics. It uses a multiple-model, Bayesian adaptive control algorithm to find the maximally precise dose that will achieve a user-specified target concentration or concentrations.
Study NCT02687204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twice daily enoxaparin prophylaxis
Description: Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
Study NCT03024762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: targeted Provider-Initiated-Testing and Counseling (tPITC)
Description: The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
Study NCT02687204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Real time dose adjustment
Description: Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
Study NCT00887783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Navelbine
Description: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks
Study NCT04166526 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: Participants in Groups 1-3 will receive a single, hour-long MRI. Participants in Group 4 will receive two, one hour long MRI scans: one within a week prior to their transfusion and one within a week after their transfusion.
Study NCT04225078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide will be administered as a single oral dose at the expected therapeutic or supratherapeutic doses respectively.
Study NCT04225078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching loperamide placebo capsules will be administered orally.
Study NCT04225078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin tablets will be administered orally.
Study NCT01547689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Derived MSC
Description: 20 million cells per subject（0.5×10\^6 UC-MSCs per kg ） intravenous injection Infusion number:8 (Once every two weeks in the first month of each quarter) Time interval: two and a half months
Study NCT02065726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician + 20 g (2 x 10 g) of whey proteins
Study NCT02065726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional counseling
Description: Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician
Study NCT04389996 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Patients will be sent a survey incl. EORTC QLQ-C30
Study NCT01718613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
Study NCT01718613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
Study NCT03709056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: HSK3486 intravenous (iv) 0.4(0.5) mg/kg for induction, and 0.2 (0.15)mg/kg top-ups for maintenance. 0.3(0.375) mg/kg for induction and 0.15 (0.113)mg/kg for maintenance in adults of 65-70 years old
Study NCT03709056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol iv 2.0 mg/kg for induction, and 1.0 mg/kg top-ups for maintenance. 1.5 mg/kg for induction and 0.75mg/kg for maintenance in adults of 65-70 years old.
Study NCT00006006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Study NCT00006006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study NCT00887783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navelbine
Description: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks
Study NCT00887783 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 66 Gy/33F
Description: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)
Study NCT03011723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resource oriented music therapy
Description: 10 weeks of tailored individual music therapy for PWD and a caregiver. Pre and post assessment in addition.~The music therapy consists of one or more of the following activities:~1. Singing~2. Listening to live music~3. Listening to recorded music~4. Dancing~5. Conversations about memories/reminiscence~6. Exercising to music~7. Breathing exercises and relaxing exercises~The treatment is following the principles of resource oriented music therapy as described by Rolvsjord et al (2005)
Study NCT03620630 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: myCOPD
Description: myCOPD is a multi faceted web based application designed to support people with COPD in the Long term management of their COPD.
Study NCT01530672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MBIO POC combined HIV syphilis test ( SnapEsi)
Description: Venipuncture for routine ANC screening plus additional for device validation purposes.
Study NCT01286441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% EISO
Description: During the Treatment Period, subjects will apply study medication (10% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Study NCT01011322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-02
Description: Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks
Study NCT00887783 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 60 Gy/30F
Description: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)
Study NCT02632409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01286441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the Treatment Period, subjects will apply placebo to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Study NCT02632409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01604980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein intake.
Description: protein intakes will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8 and 2.0g/kg/day
Study NCT01286441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% EISO
Description: During the Treatment Period, subjects will apply study medication (20% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Study NCT01286441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% EISO
Description: During the Treatment Period, subjects will apply study medication (30% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Study NCT01011322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02101086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: Whenever the infant indicated to receive transfusion, a blood product request was sent to the blood bank. This infant was randomly assigned to the autologous or the allogeneic product labeled for each patient at birth in the blood bank
Study NCT00882622 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line.
Study NCT00882622 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control/sham procedure
Description: Sham placement of the blood pressure cuff around the upper limb without inflation.
Study NCT02387320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Care Toolkit
Description: The self-care toolkit was designed and created for individuals undergoing surgery and/or invasive medical procedures. It provides individuals with guided instruction to learn several evidence-informed mind-body skills (e.g., breathing, relaxation, meditation, guided imagery) and tools (e.g., acupressure wristbands, journal) in order to regulate their own physiologic and emotional reactions to stressful situations and to lessen symptoms associated with surgery (principally pain, anxiety, nausea, fatigue, sleep disturbance).
Study NCT02101086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: Whenever the infant indicated to receive transfusion, a blood product request was sent to the blood bank. This infant was randomly assigned to the autologous or the allogeneic product labeled for each patient at birth in the blood bank
Study NCT01436201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally
Study NCT01436201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered as subcutaneous injection
Study NCT00524225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neumega (Oprelvekin, Interleukin 11, IL-11)
Description: 25 micrograms/kg by subcutaneous injection once daily for four days, followed by once daily on days 1-3 before and after elective surgery or dental procedure
Study NCT00110890 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cinacalcet
Description: Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg.
Study NCT00110890 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Standard of care
Description: Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.